In cholangiocarcinoma, GLUT5 inhibition reduces fructose uptake and tumor cell invasion, whereas in lung cancer, it is markedly upregulated, accelerating in vivo tumor growth [41,42]. This evidence concerns the gene SLC2A5 and lung cancer.